Corvus Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview

Corvus Pharmaceuticals

30/10/2023 12:06

* Corvus Pharmaceuticals Inc  CRVS.OQ   CRVS.O  is expected
to show no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Corvus
Pharmaceuticals
Inc is for a loss of 12 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Corvus
Pharmaceuticals Inc is $8​, above​ its last closing price
of $1.12. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.16       -0.14      -0.14     Met     -0.5
 Mar. 31 2023  -0.16       -0.16      -0.17     Missed  -8.3
 Dec. 31 2022  -0.25       -0.23      -0.21     Beat    9.1​
 Sep. 30 2022  -0.16       -0.16      -0.32     Missed  -104.3
 ​​Jun.        -0.17       -0.18      -0.18     Met     -1.9
 30 2022                                                
 Mar. 31 2022  -0.15       -0.15      -0.18     Missed  -17.4​
 Dec. 31 2021  -0.18       -0.19      -0.20     Missed  -6.7
 Sep. 30 2021  -0.24       -0.26      -0.24     Beat    6.5
 This summary was machine generated October 30 at 12:06 GMT.  All
figures in US dollars  unless otherwise stated